265 results on '"Molina-Vila, Miguel-Angel"'
Search Results
2. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways
3. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
4. Gene expression signatures in conjunctival fornix aspirates of patients with dry eye disease associated with Meibomian gland dysfunction. A proof-of-concept study
5. Liquid biopsy in detecting early non-small cell lung cancer
6. Overcoming MET-mediated resistance in oncogene-driven NSCLC
7. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
8. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
9. HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
10. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung
11. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
12. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
13. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
14. Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
15. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
16. Panels and models for accurate prediction of tumor mutation burden in tumor samples
17. Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation
18. Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial
19. Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells
20. RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants
21. Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC
22. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
23. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
24. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
25. Fluorescence In Situ Hybridization (FISH) for the Characterization and Monitoring of Primary Cultures from Human Tumors
26. PD.02.02 Lung TS: A New 6-Gene Signature for Prediction of Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients
27. Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
28. PSP.01 Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis
29. Disruptive and Truncating TP53 Mutations Are Associated with African-Ancestry and Worse Prognosis in Brazilian Patients with Lung Adenocarcinoma
30. RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center
31. KRAS Mutations in Lung Cancer
32. BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
33. LungTS: A new gene expression signature for prediction of response to checkpoint inhibitors in non-small cell lung cancer.
34. Digital multiplexed analysis of circular RNAs in FFPE and fresh non‐small cell lung cancer specimens
35. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
36. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
37. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
38. LungTS: A new gene expression signature for prediction of response to checkpoint inhibitors in non-small cell lung cancer
39. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
40. Abstract 290: Comparison of clinically relevant fusions detection using two multiplexing RNA based platforms: nCounter and GeneReader
41. Abstract 409: A pre-treatment plasma extracellular vesicle-mRNA signature associates with checkpoint inhibitor pneumonitis in lung cancer patients
42. Abstract 951: Evolution of antibody titers, growth factor levels andin vitroactivity in the sera of patients enrolled in the EPICAL trial of afatinib combined with anti-EGF vaccination
43. Abstract 1107: Precision phosphoproteomic analysis in Chr22q11.2 amplified NSCLC cells reveals distinct signaling corruption and response to Aurora kinase B inhibition
44. Abstract 469: Comprehensive, large scale analysis of ALK, ROS1, RET, NTRK1 and NRG1 transcripts in lung cancer reveals over-expressing, potentially targetable patients
45. Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients.
46. Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.
47. Validation of liquid biopsy-based analysis on the NanoString nCounter platform
48. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer
49. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
50. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.